Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis

1998 ◽  
Vol 132 (6) ◽  
pp. 983-988 ◽  
Author(s):  
Marina Giuliano ◽  
Paola Mastrantonio ◽  
Anna Giammanco ◽  
Annunziata Piscitelli ◽  
Stefania Salmaso ◽  
...  
Keyword(s):  
Antibody Responses ◽  
Cell Vaccine ◽  
Whole Cell ◽  
Whole Cell Vaccine ◽  
Acellular Vaccines

scholarly journals Antibody Responses to Bordetella pertussis Fim2 or Fim3 following Immunization with a Whole-Cell, Two-Component, or Five-Component Acellular Pertussis Vaccine and following Pertussis Disease in Children in Sweden in 1997 and 2007

2013 ◽  
Vol 21 (2) ◽  
pp. 165-173 ◽  
Author(s):  
Hans Hallander ◽  
Abdolreza Advani ◽  
Frances Alexander ◽  
Lennart Gustafsson ◽  
Margaretha Ljungman ◽  
...  
Keyword(s):  
Pertussis Vaccine ◽  
Bordetella Pertussis ◽  
Geometric Mean ◽  
Acellular Pertussis Vaccine ◽  
Antibody Responses ◽  
Cell Vaccine ◽  
Whole Cell ◽  
Content Type ◽  
Two Component ◽  
Whole Cell Vaccine

ABSTRACTBordetella pertussisfimbriae (Fim2 and Fim3) are components of a five-component acellular pertussis vaccine (diphtheria–tetanus–acellular pertussis vaccine [DTaP5]), and antibody responses to fimbriae have been associated with protection. We analyzed the IgG responses to individual Fim2 and Fim3 in sera remaining from a Swedish placebo-controlled efficacy trial that compared a whole-cell vaccine (diphtheria-tetanus-whole-cell pertussis vaccine [DTwP]), a two-component acellular pertussis vaccine (DTaP2), and DTaP5. One month following three doses of the Fim-containing vaccines (DTwP or DTaP5), anti-Fim2 geometric mean IgG concentrations were higher than those for anti-Fim3, with a greater anti-Fim2/anti-Fim3 IgG ratio elicited by DTaP5. We also determined the responses in vaccinated children following an episode of pertussis. Those who received DTaP5 showed a large rise in anti-Fim2 IgG, reflecting the predominant Fim2 serotype at the time. In contrast, those who received DTwP showed an equal rise in anti-Fim2 and anti-Fim3 IgG concentrations, indicating that DTwP may provide a more efficient priming effect for a Fim3 response following contact withB. pertussis. Anti-Fim2 and anti-Fim3 IgG concentrations were also determined in samples from two seroprevalence studies conducted in Sweden in 1997, when no pertussis vaccine was used and Fim2 isolates predominated, and in 2007, when either DTaP2 or DTaP3 without fimbriae was used and Fim3 isolates predominated. Very similar distributions of anti-Fim2 and anti-Fim3 IgG concentrations were obtained in 1997 and 2007, except that anti-Fim3 concentrations in 1997 were lower. This observation, together with the numbers of individuals with both anti-Fim2 and anti-Fim3 IgG concentrations, strongly suggests thatB. pertussisexpresses both Fim2 and Fim3 during infection.

Comparison of 13 Acellular Pertussis Vaccines: Adverse Reactions

PEDIATRICS ◽  
1995 ◽  
Vol 96 (3) ◽  
pp. 557-566
Author(s):  
Michael D. Decker ◽  
Kathryn M. Edwards ◽  
Mark C. Steinhoff ◽  
Margaret B. Rennels ◽  
Michael E. Pichichero ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Cell Vaccine ◽  
Whole Cell ◽  
The Third ◽  
Efficacy Trials ◽  
Healthy Infants ◽  
Long Term Follow Up ◽  
Whole Cell Vaccine ◽  
Acellular Vaccines

Objective. To compare the reactogenicity of a licensed conventional whole-cell (WCL) and 13 acellular pertussis vaccines that differed in the source, manufacture, and quantity of included antigens; all vaccines included diphtheria and tetanus toxoids. Methods. Healthy infants were enrolled through six university-based vaccine and treatment evaluation units and were randomized to receive one of the study vaccines at 2, 4, and 6 months of age. Parents recorded the occurrence of fever, redness, swelling, pain, fussiness, drowsiness, anorexia, and use of antipyretics for 2 weeks after each inoculation; nurses interviewed parents on the third day and at each succeeding visit; long-term follow-up information was collected from parents and medical records 1 year after the third immunization. Results. Of 2200 vaccinated infants, 2189 contributed reaction data after 6375 vaccinations. For every acellular vaccine, every monitored reaction except vomiting occurred at a significantly lower frequency and severity than was seen with WCL. The groups receiving acellular pertussis vaccines differed significantly with respect to redness, swelling, pain, and vomiting, but not with respect to fussiness, antipyretic use, drowsiness, or anorexia. Conclusion. Although there were differences among the acellular vaccines, none was consistently the most or least reactogenic; all were associated with substantially fewer and less severe adverse reactions than a standard commercial whole-cell vaccine. Selection of acellular vaccines for further development and for introduction into efficacy trials can give priority to assessments of immunogenicity and purity, with comparative reactogenicity a secondary consideration.

scholarly journals Immunogenicity and efficacy of Heat Inactivated Whole-Cell Vaccine to increase murine survival after Extensively drug-resistant Acinetobacter baumannii infection.

2021 ◽  
Author(s):  
Nazmun Sharmin ◽  
Mahbub E Khoda ◽  
S. M. Shamsuzzaman ◽  
Mohammad Nazim Uddin
Keyword(s):  
Lethal Dose ◽  
Antibody Responses ◽  
Cell Vaccine ◽  
Drug Resistant ◽  
Igg Antibody ◽  
Whole Cell ◽  
Extensively Drug Resistant ◽  
Intramuscular Inoculation ◽  
Whole Cell Vaccine ◽  
Experimental Group

Due to the rapid emergence of extensively drug-resistant (XDR) strains worldwide there is a necessity for greater consideration for the role of preventive vaccines to combat these pathogens. The study reported the effectiveness of a heat-inactivated whole-cell vaccine (HI-WCV) against A. baumannii to produce protective immunity with evaluation of the bactericidal antibody responses in mice after intramuscular inoculation with different XDR strains of A. baumannii Six XDR A. baumannii strains emulsified with complete freund's adjuvant (CFA) were used for intramuscular inoculation in the experimental group of mice (n=4) in three different phases on 14 days interval whereas placebo-controlled mice (n=4) received phosphate-buffered saline emulsified with CFA in same the schedule. Serum was collected from tail blood of each mouse on 10th day after each inoculation and by cardiac puncture on 14th day after lethal dose from the experimental group and after death of the placebo-controlled group. Mice inoculated with heat-inactivated whole-cell vaccine survived and showed a higher neutralizing (IgG) antibody response after 2nd (>7-fold titre) and 3rd inoculation (>12-fold titre) whereas all mice from placebo-controlled group did not survived. Sera from experimental group of mice collected (38th day) after 3rd inoculation resulted in higher serum bactericidal killing index (42.12) after three hours incubation with an XDR A. baumannii over sera collected after 1st and 2nd inoculation (50% cutoff value=14.5). These results suggest that intramuscular vaccination with heat-inactivated whole-cell vaccine stimulated IgG antibody responses that can increase murine survival after XDR A. baumannii infection.

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

1996 ◽  
Vol 334 (6) ◽  
pp. 341-349 ◽  
Author(s):  
Donato Greco ◽  
Stefania Salmaso ◽  
Paola Mastrantonio ◽  
Marina Giuliano ◽  
Alberto E. Tozzi ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Cell Vaccine ◽  
Whole Cell ◽  
Whole Cell Vaccine ◽  
Acellular Vaccines

scholarly journals Temporal trends in circulating Bordetella pertussis strains in Australia

2004 ◽  
Vol 132 (2) ◽  
pp. 185-193 ◽  
Author(s):  
M. POYNTEN ◽  
P. B. McINTYRE ◽  
F. R. MOOI ◽  
K. J. HEUVELMAN ◽  
G. L. GILBERT
Keyword(s):  
Bordetella Pertussis ◽  
Older Persons ◽  
Vaccine Coverage ◽  
Temporal Trends ◽  
Cell Vaccine ◽  
Whole Cell ◽  
Rflp Type ◽  
Whole Cell Vaccine ◽  
Waning Immunity ◽  
Acellular Vaccines

Australia experienced a resurgence of pertussis in the 1990s despite improved vaccine coverage. Although much of the increase was attributable to increased detection of cases in older persons with waning immunity by serology, vaccine changes or alterations in circulating Bordetella pertussis strains may also have contributed. We determined the frequency of variants of B. pertussis pertactin (prn), and pertussis toxin subunit 1 (ptxS1) genes, restriction fragment length polymorphism (RFLP) types and fimbrial serotypes prevalent in Australia prior to, and during the 1990s. Ampoules of the whole-cell vaccine in use prior to 1999 and 84 B. pertussis isolates stored between 1967 and 1998 by laboratories around Australia were analysed. One pertactin allele, Prn3, not detected before 1985, was found in 24 out of 57 (42%) isolates between 1989 and 1998 (P<0·0001). PtxS1A was found in all isolates. IS1002 type 29, found in 17 out of 31 (55%) isolates tested, was the predominant RFLP type. The only difference in fimbrial serotype distribution between the time-periods was an increase in serotype 3 (P=0·054). The whole-cell vaccine contained only the alleles prn1 and ptxS1A. Antigenic shift in B. pertussis may have contributed to the re-emergence of pertussis in Australia. Monitoring these trends will be important as acellular vaccines are introduced and changes are made to pertussis vaccine schedules.

Primary Immunization of Infants With an Acellular Pertussis Vaccine in a Double-Blind Randomized Clinical Trial

PEDIATRICS ◽  
1988 ◽  
Vol 82 (3) ◽  
pp. 293-299
Author(s):  
Margareta Blennow ◽  
Marta Granström ◽  
Eva Jäätmaa ◽  
Patrick Olin
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Pertussis Vaccine ◽  
Acellular Pertussis Vaccine ◽  
Cell Vaccine ◽  
Primary Immunization ◽  
Double Blind ◽  
Whole Cell ◽  
Whole Cell Vaccine ◽  
Acellular Vaccine

The rate of adverse reactions and the immunogenicity of a two-component acellular pertussis vaccine as compared with a plain whole-cell vaccine and a placebo were evaluated for primary immunization in 319 6-month-old infants in a double-blind randomized clinical trial. The acellular vaccine produced few and mild systemic and local reactions. Fever (≥38°C) occurred in 6% to 8% of acellular vaccinees as opposed to 25% to 37% of whole-cell vaccinees. Redness (≥1 cm) appeared in 2% to 13% of the acellular vaccine and 24% to 32% of the whole-cell vaccine recipients. Antibody response to pertussis toxin measured in a neutralization test was obtained in 97% to 100% of the infants receiving either two or three doses of the acellular vaccine as compared to 59% after three doses of whole-cell vaccine.

scholarly journals PERTUSSIS INCIDENCE AND THE EFFECT OF REVACCINATION OF PRESCHOOL AND SCHOOL CHILDREN

2018 ◽  
Vol 8 (3) ◽  
pp. 284-294 ◽  
Author(s):  
А. M. Kostinov ◽  
M. P. Kostinov
Keyword(s):  
Favorable Effect ◽  
Cell Vaccine ◽  
School Age ◽  
Pertussis Infection ◽  
Whole Cell ◽  
Number Of Factors ◽  
Foreign Countries ◽  
Incidence And Mortality ◽  
Whole Cell Vaccine ◽  
Cytomegalovirus Infections

The review is devoted to the analysis of pertussis incidence of children in the age group of 5–7, as well as strategies of DTP immunization with the help of the drugs in foreign countries. Mass vaccination against pertussis began in the middle of the 20th century, which contributed to a reduction in incidence and mortality rate from this infection. However, in the last decade, there has been an opposite tendency of increasing incidence of patients among children under school age, school age and adults. Atypical forms of the disease and complications due to ARVI, respiratory mycoplasmosis and cytomegalovirus infections are described in the review. Various strategies for the use of whole-cell and acellular pertussis vaccines as part of DTP drugs are described, as well as the epidemiological effect of introducing an additional booster dose of vaccine to children under school age. The expediency of revaccination of children aged 6–7 in Russia is argued, which can help to reduce the overall incidence of pertussis. The research materials related to the study of the properties of acellular anti-pertussis vaccine, such as immunogenicity and safety in comparison with whole-cell vaccine, are analyzed. The main drugs and their composition, which are used to vaccinate children against pertussis, are described in the review. It is assumed, that the increase in the incidence among children and teenagers, with the appearance of atypical forms of pertussis, is associated with a number of factors, such as the spread of new genotypes of Bordetella pertussis bacterium, emerged from mutations, as well as short duration of immunity after vaccination with acellular drugs, in comparison with whole-cell, and the use of more modern methods of detecting the pathogen. The mechanisms of the immune response due to different types of pertussis vaccines are also reviewed. It is concluded, that revaccination of children aged 6–7 with an additional fifth dose of an acellular vaccine against pertussis, as part of the DTaP instead of the Td drug, which is regulated in the National Calendar of preventive vaccinations, will have a favorable effect on the epidemic situation with pertussis infection in Russia.

Sign in / Sign up

Export Citation Format

Share Document